One spring day in April, I was confronted with an ethical and economic challenge that is emblematic of the social and economic challenge the United States is facing regarding health care. The cost of health care in the United States is expensive-it accounts for one-sixth of the US economy, and it is perhaps the greatest threat to the long-term solvency of our state and federal governments. You have probably heard about this in some form over the past few years, but the reality of the problem is striking when a patient is sitting in your office.
I evaluated a young Division III collegiate athlete in my office outside of Boston; she was injured during a lacrosse tournament. The history suggested an anterior cruciate ligament tear; the physical examination confirmed the diagnosis. Our discussion turned toward the timing of surgery, the graft source, the rehabilitation process, and the potential for repair of cartilage and meniscal injuries. Simply by routine I order an MRI scan before surgery to confirm the diagnosis and evaluate the knee for secondary injuries-I suspect that many of you have the same routine. There was an awkward uneasiness in the exam room as we discussed the logistics of obtaining an MRI scan and scheduling the surgery. I soon learned that the family had a high-deductible health insurance plan, and an MRI scan would be an ''out of pocket'' expense. The ACL tear created an unexpected budget crisis for the family, and the cost of treatment for the injury would rival the cost of a semester at college.
In the United States, the past 5 years have witnessed a quiet yet dynamic shift in health care benefits provided to employees by employers. Perhaps in an attempt to compete in a global economy while maintaining profitability, many companies are shifting the burden of paying for health care squarely onto the shoulders of their employees. There has been an astonishing proliferation of highdeductible insurance plans and cost-sharing plans that cover a fraction of the total medical expense. These changes have created price sensitivity in the health care marketplace. Patients are now searching for value and acting like true consumers.
Simultaneously, the implementation of the Affordable Care Act (ACA) catalyzed the proliferation of new types of contracts between payers, providers, and patients. The national debate regarding the ACA of 2010 has focused primarily on who is covered, what services should be provided, and who should pay for it. While the public attention has been drawn to the sharp rhetoric and conflict regarding the new law, one of the most crucial components of the ACA has quietly gone unnoticed. The new contracts move away from a transactional-based, fee-for-service model that historically has rewarded volume and the provision of more services. The new, value-based contracts reward value-now commonly understood as outcomes divided by costs.
Value = Outcomes/Cost
Value-based contracts are gaining momentum throughout the United States, and unlike health care reform in the 1990s, it appears that there is no going back at this point. 3 In this way the insurance payers, both the Centers for Medicare and Medicaid Services (CMS) and commercial, are acting like consumers-much like my lacrosse family.
The good news is that orthopaedic surgery, especially sports medicine, is ahead of these changes in health care delivery. We have been a leader among the other medical specialties in defining and reporting our results, and we have developed validated patient-reported outcome measures. It is unambiguous that on the outcomes side of the value equation we have performed well.
Our performance on the cost side of the value equation, however, requires a more detailed analysis, and the majority of hospitals are not able to accurately determine the total cost of an episode of care. For example, the development and rapid diffusion of new and innovative technology in the past decade has been an integral component to the success of sports medicine and our superb patient outcomes. However, there are many examples of noninnovative technologies being introduced that simply add an incremental cost to each surgical procedure without improving the outcome. We are now confronted with a nearly impossible task: ''bend the cost curve'' and provide those same superb outcomes, but at a reduced cost. That's creating value at the individual patient level.
There has been a paucity of manuscripts in AJSM and other orthopaedic journals regarding value, outcomes, and cost. We are now starting to publish articles reporting outcome measures such as quality-adjusted life-years, the cost-effectiveness analysis, and the incremental cost effectiveness ratio. 1 If all this makes you feel a bit uncomfortable, it should. I have immersed myself in this field over the past several years while obtaining a master's degree at The Dartmouth Institute for Health Policy and Clinical Practice and the Tuck School of Business, but I feel much more comfortable discussing the nuances of shoulder and knee surgery. I promise that the AJSM Current Concepts section will continue to focus on orthopaedic sports medicine, but as health care delivery transitions from volume to value, we will also be at the forefront of publishing high-quality articles addressing these changes in sports medicine. 1, 2 Keywords: value-based health care; Affordable Care Act; cost-effectiveness analysis Returning to my patient, she had an anatomic ACL reconstruction with autograft hamstring tendons and a partial lateral meniscectomy. I used a button for the femoral fixation and an interference screw for the tibial fixation. As for the MRI, it was a shared decision not to obtain advanced imaging. We can only provide value to one patient at a time, but thousands of us working in our own hospital or clinic settings, and working within our own geographic areas across the globe, have the ability to redefine value in sports medicine.
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